Shan Fu

New Frontier Health Corp. is a private healthcare provider offering healthcare services in China. The firm's United Family Healthcare platform consists of a network of seven private hospitals and affiliated ambulatory clinics. It's 700 licensed inpatient beds, together with its clinic network, spans eight metropolitan areas, including all four 1st tier cities in China. The company was founded by Kam Chung Leung and Carl Wu on March 28, 2018 and is headquartered in Hong Kong.

Esco Lifesciences Group Ltd. is a multinational life sciences company, engages in the development, manufacture, and sale of life sciences, pharmaceutical and bioprocessing tools as well as the offering of related after-sales and support services. It operates through the following segments: Esco Scientific, Esco Medical, Esco Healthcare, and Esco Services. The Esco Scientific segment provides mission critical life sciences laboratory equipment such as biological safety cabinets, laminar flow clean benches, CO2 and CO2/O2 incubators, fume hoods, centrifuges and others used in research, clinical and industrial settings for preparation, cultivation, handling and analytical purposes. The Esco Medical segment manufactures and sells medical devices such as incubators, workstations, and consumables for IVF treatment. The Esco Healthcare segment provides pharmaceutical equipment and bioprocessing tools, primarily containment and isolation systems for the production of medicines, vaccines, and cell and gene therapies. The Esco Services segment offers after-sales and support services to customers of Esco Scientific, Esco Medical, and Esco Healthcare. The company was founded on February 1, 2021 and is headquartered in Singapore.

Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.

VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.

VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction.